ClinicalTrials.gg
CompletedNCT01881113Updated Nov 9, 2017Results posted

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

A Phase 3 interventional study of AC-170 0.24% and AC-170 0% in Allergic Conjunctivitis, sponsored by Aciex Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2017-11-09.

Sponsored by Aciex Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.

Enrollment
39th of 90
101 · median 94
Started
2013
with 4 others
Phase 3
34 of 95
2 open now
Registered
59th of 95
by date
Lead sponsor
6 of 95
Aciex Therapeutics, Inc.

Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 39th largest by enrollment of the 90 interventional ones that give a count, is one of 5 that started in 2013, is one of 34 in phase 3, and was the 59th registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Conjunctivitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.

03

Conditions studied

  • Allergic Conjunctivitis
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • positive bilateral conjunctival allergen challenge (CAC) reaction

Exclusion criteria

Exclusion Criteria:

  • known or sensitivities to the study medication or its components
  • any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters
  • use of disallowed medication during the period indicated prior to the enrollment or during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    AC-170 0.24%

    Drug: AC-170 0.24%

  • Placebo comparator
    AC-170 0%

    Drug: AC-170 0%

Interventions

  • 1 drop in each eye at 2 separate times during a 14 day period

  • DrugAC-170 0%

    1 drop in each eye at 2 separate times during a 14 day period

06

What researchers measure

Primary outcomes

  1. Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

    Time frame: 3, 5, 7 minutes post-CAC

  2. Ocular Itching at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

    Time frame: 3, 5, 7 minutes post-CAC

  3. Conjunctival Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  4. Conjunctival Redness at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

Secondary outcomes

  1. Ciliary Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  2. Ciliary Redness at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  3. Episcleral Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  4. Episcleral Redness at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  5. Chemosis at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  6. Chemosis at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  7. Eyelid Swelling at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  8. Eyelid Swelling at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  9. Tearing at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  10. Tearing at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  11. Rhinorrhea at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  12. Rhinorrhea at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  13. Nasal Pruritus at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  14. Nasal Pruritus at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  15. Ear or Palate Pruritus at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  16. Ear or Palate Pruritus at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  17. Nasal Congestion at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  18. Nasal Congestion at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  19. Percentage of Participants With At Least One Nasal Symptom at Duration of Action (8 Hours + 30 Minutes Post-Dose)

    A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  20. Percentage of Participants With At Least One Nasal Symptom at Onset of Action (15 Minutes Post-Dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  21. Tolerability of Study Medication at Visit 3A

    Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.

    Time frame: upon instillation, 1 minute and 2 minutes post instillation

07

Results

Posted Nov 9, 2017

Participant flow

Subjects were recruited from three sites in the US.

Participant flow — Overall Study
MilestoneAC-170 0.24%AC-170 0%
Started5150
Completed4344
Not completed86

Outcome measures

PrimaryOcular Itching at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

Time frame:
3, 5, 7 minutes post-CAC
Reported as:
Mean · units on a scale
Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
3 minutes post-CAC1.94 ± 0.9332.86 ± 0.748
5 minutes post-CAC2.03 ± 0.9472.94 ± 0.712
7 minutes post-CAC1.82 ± 1.0262.66 ± 0.809
PrimaryOcular Itching at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

Time frame:
3, 5, 7 minutes post-CAC
Reported as:
Mean · units on a scale
Ocular Itching at Onset of Action (15 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
3 minutes post-CAC1.01 ± 1.0062.54 ± 0.943
5 minutes post-CAC1.17 ± 1.0022.51 ± 0.875
7 minutes post-CAC1.15 ± 1.0062.23 ± 0.956
PrimaryConjunctival Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Conjunctival Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC1.97 ± 0.7022.39 ± 0.619
15 minutes post-CAC2.13 ± 0.6392.38 ± 0.602
20 minutes post-CAC2.09 ± 0.7012.40 ± 0.639
PrimaryConjunctival Redness at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Conjunctival Redness at Onset of Action (15 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC1.92 ± 0.7132.38 ± 0.653
15 minutes post-CAC2.19 ± 0.6082.37 ± 0.661
20 minutes post-CAC2.15 ± 0.6462.41 ± 0.651
SecondaryCiliary Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Ciliary Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC1.71 ± 0.7942.15 ± 0.689
15 minutes post-CAC1.93 ± 0.7532.05 ± 0.777
20 minutes post-CAC1.87 ± 0.8012.19 ± 0.659
SecondaryCiliary Redness at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Ciliary Redness at Onset of Action (15 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC1.62 ± 0.9452.29 ± 0.803
15 minutes post-CAC2.05 ± 0.7932.34 ± 0.780
20 minutes post-CAC2.09 ± 0.7792.36 ± 0.784
SecondaryEpiscleral Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Episcleral Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC1.92 ± 0.6622.29 ± 0.567
15 minutes post-CAC2.08 ± 0.6632.27 ± 0.605
20 minutes post-CAC2.06 ± 0.6892.30 ± 0.640
SecondaryEpiscleral Redness at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Episcleral Redness at Onset of Action (15 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC1.91 ± 0.7982.31 ± 0.575
15 minutes post-CAC2.22 ± 0.6452.32 ± 0.582
20 minutes post-CAC2.18 ± 0.6552.36 ± 0.604
SecondaryChemosis at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Chemosis at Duration of Action (8 Hours + 30 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.63 ± 0.5400.96 ± 0.666
15 minutes post-CAC0.89 ± 0.6271.28 ± 0.773
20 minutes post-CAC0.95 ± 0.7531.27 ± 0.785
SecondaryChemosis at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Chemosis at Onset of Action (15 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.35 ± 0.3870.58 ± 0.519
15 minutes post-CAC0.59 ± 0.5850.75 ± 0.671
20 minutes post-CAC0.67 ± 0.6260.85 ± 0.702
SecondaryEyelid Swelling at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Eyelid Swelling at Duration of Action (8 Hours + 30 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.7 ± 0.701.4 ± 0.78
15 minutes post-CAC0.8 ± 0.711.4 ± 0.80
20 minutes post-CAC0.9 ± 0.911.4 ± 0.89
SecondaryEyelid Swelling at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Eyelid Swelling at Onset of Action (15 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.4 ± 0.671.2 ± 0.63
15 minutes post-CAC0.5 ± 0.761.3 ± 0.75
20 minutes post-CAC0.4 ± 0.701.2 ± 0.77
SecondaryTearing at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Tearing at Duration of Action (8 Hours + 30 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.8 ± 0.671.2 ± 0.81
15 minutes post-CAC0.8 ± 0.901.2 ± 0.94
20 minutes post-CAC0.9 ± 0.981.0 ± 1.01
SecondaryTearing at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Tearing at Onset of Action (15 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.5 ± 0.611.1 ± 0.89
15 minutes post-CAC0.5 ± 0.621.1 ± 0.90
20 minutes post-CAC0.5 ± 0.651.0 ± 0.94
SecondaryRhinorrhea at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Rhinorrhea at Duration of Action (8 Hours + 30 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.6 ± 0.851.1 ± 0.88
15 minutes post-CAC0.8 ± 0.891.3 ± 1.00
20 minutes post-CAC1.0 ± 1.011.3 ± 1.06
SecondaryRhinorrhea at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Rhinorrhea at Onset of Action (15 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.5 ± 0.701.3 ± 1.05
15 minutes post-CAC0.7 ± 0.891.3 ± 1.12
20 minutes post-CAC0.8 ± 0.781.1 ± 1.05
SecondaryNasal Pruritus at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Nasal Pruritus at Duration of Action (8 Hours + 30 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.5 ± 0.790.9 ± 0.99
15 minutes post-CAC1.0 ± 1.011.0 ± 1.11
20 minutes post-CAC0.9 ± 1.000.9 ± 0.96
SecondaryNasal Pruritus at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Nasal Pruritus at Onset of Action (15 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.4 ± 0.760.8 ± 0.87
15 minutes post-CAC0.6 ± 1.050.8 ± 0.99
20 minutes post-CAC0.6 ± 0.870.9 ± 0.95
SecondaryEar or Palate Pruritus at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Ear or Palate Pruritus at Duration of Action (8 Hours + 30 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.4 ± 0.731.2 ± 1.10
15 minutes post-CAC0.8 ± 1.001.5 ± 1.25
20 minutes post-CAC1.0 ± 1.141.6 ± 1.27
SecondaryEar or Palate Pruritus at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Ear or Palate Pruritus at Onset of Action (15 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.3 ± 0.740.8 ± 0.96
15 minutes post-CAC0.6 ± 1.051.3 ± 1.17
20 minutes post-CAC0.7 ± 1.061.3 ± 1.24
SecondaryNasal Congestion at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Nasal Congestion at Duration of Action (8 Hours + 30 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.5 ± 0.681.0 ± 0.89
15 minutes post-CAC0.8 ± 0.851.4 ± 1.08
20 minutes post-CAC1.1 ± 1.081.3 ± 1.00
SecondaryNasal Congestion at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Nasal Congestion at Onset of Action (15 Minutes Post-Dose)
units on a scaleAC-170 0.24%AC-170 0%
7 minutes post-CAC0.4 ± 0.731.1 ± 1.13
15 minutes post-CAC0.5 ± 0.861.3 ± 1.17
20 minutes post-CAC0.6 ± 0.851.3 ± 1.14
SecondaryPercentage of Participants With At Least One Nasal Symptom at Duration of Action (8 Hours + 30 Minutes Post-Dose)

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Number · % of participants
Percentage of Participants With At Least One Nasal Symptom at Duration of Action (8 Hours + 30 Minutes Post-Dose)
% of participantsAC-170 0.24%AC-170 0%
7 minutes post-CAC5887.5
15 minutes post-CAC7889.6
20 minutes post-CAC8489.6
SecondaryPercentage of Participants With At Least One Nasal Symptom at Onset of Action (15 Minutes Post-Dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Number · % of participants
Percentage of Participants With At Least One Nasal Symptom at Onset of Action (15 Minutes Post-Dose)
% of participantsAC-170 0.24%AC-170 0%
7 minutes post-CAC51.281.8
15 minutes post-CAC58.186.4
20 minutes post-CAC72.188.6
SecondaryTolerability of Study Medication at Visit 3A

Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.

Time frame:
upon instillation, 1 minute and 2 minutes post instillation
Reported as:
Mean · units on a scale
Tolerability of Study Medication at Visit 3A
units on a scaleAC-170 0.24%AC-170 0%
Upon instillation1.6 ± 2.020.8 ± 1.22
1 minute post-instillation3.0 ± 2.331.1 ± 1.14
2 minutes post-instillation2.6 ± 2.141.1 ± 1.13

Adverse events

Collected over Adverse events were collected through study completion, an average of 5 weeks.. All subjects who received study medication were evaluable for the safety analysis.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AC-170 0.24%—0/51 (0%)3/51 (5.9%)
AC-170 0%—0/50 (0%)5/50 (10%)
Most frequent other events
Most frequent other events
EventAC-170 0.24%AC-170 0%
Visual acuity reducedEye disorders1/511/50
EpistaxisRespiratory, thoracic and mediastinal disorders0/511/50
Rhinitis allergicRespiratory, thoracic and mediastinal disorders0/511/50
Road traffic accidentInjury, poisoning and procedural complications0/511/50
Varicose veinVascular disorders0/511/50
Dermatitis contactSkin and subcutaneous tissue disorders1/510/50
Neck painMusculoskeletal and connective tissue disorders1/510/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)AC-170 0.24%AC-170 0%Total
Mean40.6 ± 12.839.2 ± 10.8439.9 ± 11.84
Sex: Female, Male
Sex: Female, Male(Participants)AC-170 0.24%AC-170 0%Total
Female122032
Male393069
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AC-170 0.24%AC-170 0%Total
Hispanic or Latino101
Not Hispanic or Latino5050100
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AC-170 0.24%AC-170 0%Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American101727
White413172
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)AC-170 0.24%AC-170 0%Total
United States5150101
08

Study locations

1 site
  • Ora, Inc.
    Andover, Massachusetts 01810, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2017, 4 years 1 month after primary completion. A results delay was requested in Apr 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2013
First posted
Jun 19, 2013
Start
Jun 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results delay requested
Apr 30, 2015
Results first posted
Nov 9, 2017
Last update
Nov 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01881113
Lead sponsor
Aciex Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 19, 2013
Start date
Jun 2013
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Nov 9, 2017
Last update
Nov 9, 2017

Study contacts

Eugene McLaurin, MD
principal investigator · Total Eye Care, PA
Edward Meier, MD
principal investigator · Eye Care Associates of Greater Cincinnati
Mark Bergmann, MD
principal investigator · Eye Care Associates of Greater Cincinnati

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetirizine

Start the discussion